What is HC Wainwright's Estimate for RNTX FY2030 Earnings?

Key Points

• HC Wainwright raised its FY2030 EPS estimate for Rein Therapeutics to $0.56, up from $0.55, while maintaining a “Buy” rating.
• Rein Therapeutics reported quarterly EPS of -$0.10, beating the consensus estimate of -$0.27 by $0.17.
• Analyst sentiment is mixed, with a consensus rating of “Hold” and a $6.00 target price; shares recently traded down 8.5% to about $0.77.

Rein Therapeutics Inc. (NASDAQ:RNTX - Free Report) - Equities researchers at HC Wainwright increased their FY2030 earnings per share estimates for shares of Rein Therapeutics in a report released on Tuesday, August 18th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.56 per share for the year, up from their prior estimate of $0.55. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Rein Therapeutics' current full-year earnings is ($0.53) per share.

Rein Therapeutics (NASDAQ:RNTX - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.17.

Several other equities research analysts have also recently issued reports on RNTX. Weiss Ratings upgraded shares of Rein Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, August 3rd. Wall Street Zen raised shares of Rein Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 6th. Finally, Maxim Group initiated coverage on shares of Rein Therapeutics in a research note on Monday, July 20th. They set a "buy" rating and a $4.00 target price for the company. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $6.00.

Rein Therapeutics Trading Down 8.5%

Shares of RNTX opened at $0.77 on Wednesday. The business's 50 day moving average is $0.88 and its 200 day moving average is $1.13. Rein Therapeutics has a 12-month low of $0.69 and a 12-month high of $2.18. The company has a market capitalization of $65.87 million, a PE ratio of -0.45 and a beta of 1.39.

Hedge Funds Weigh In On Rein Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC bought a new stake in Rein Therapeutics in the 2nd quarter worth approximately $344,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Rein Therapeutics during the 2nd quarter valued at approximately $68,000. Cable Car Capital LP bought a new position in shares of Rein Therapeutics during the 2nd quarter valued at approximately $588,000. Vanguard Group Inc. grew its holdings in shares of Rein Therapeutics by 32.2% in the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company's stock valued at $1,338,000 after purchasing an additional 284,300 shares in the last quarter. Finally, Susquehanna International Group LLP purchased a new position in shares of Rein Therapeutics in the third quarter valued at $35,000. Hedge funds and other institutional investors own 90.89% of the company's stock.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company's core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source